Blockade of XBP1 splicing by inhibition of IRE1α is a promising therapeutic option in multiple myeloma
Open accessThe DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.
Abstract
Multiple myeloma (MM) cells are characterized by high protein synthesis resulting in chronic endoplasmic reticulum (ER) stress, which is adaptively managed by the unfolded protein response. Inositol-requiring enzyme 1α (IRE1α) is activated to splice X-box binding protein 1 (XBP1) mRNA, thereby increasing XBP1s protein, which in turn regulates genes responsible for protein folding and degradation during the unfolded protein response. In this study, we examined whether IRE1α-XBP1 pathway is a potential therapeutic target in MM using a small-molecule IRE1α endoribonuclease domain inhibitor MKC-3946. MKC-3946 triggered modest growth inhibition in MM cell lines, without toxicity in normal mononuclear cells. Importantly, it significantly enhanced cytotoxicity induced by bortezomib or 17-AAG, even in the presence of bone marrow stromal cells or exogenous IL-6. Both bortezomib and 17-AAG induced ER stress, evidenced by induction of XBP1s, which was blocked by MKC-3946. Apoptosis induced by these agents was enhanced by MKC-3946, associated with increased CHOP. Finally, MKC-3946 inhibited XBP1 splicing in a model of ER stress in vivo, associated with significant growth inhibition of MM cells. Taken together, our results demonstrate that blockade of XBP1 splicing by inhibition of IRE1α endoribonuclease domain is a potential therapeutic option in MM.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“IRE1α inhibitors KIRA8 or AMG‐18, STF083010, MKC8866 and MKC3946 reduced tumor growth in various cancers, including multiple myeloma [185, 186, 187], melanoma [188], breast cancer and prostate cancer [189].”
From Tumor microenvironment signaling and therapeutics in cancer progression (2023) · cites this paper as [187]
Citations
Cites
Yoshida, H., Matsui, T., Yamamoto, A., Okada, T., & Mori, K. (2001) · Cell · doi:10.1016/s0092-8674(01)00611-0 · Cited by 4,039
THE MAMMALIAN UNFOLDED PROTEIN RESPONSE
Schröder, M., & Kaufman, R. J. (2005) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.73.011303.074134 · Cited by 3,026
Urano, F., Wang, X., Bertolotti, A., Zhang, Y., Chung, P., Harding, H. P., & Ron, D. (2000) · Science · doi:10.1126/science.287.5453.664 · Cited by 2,988
Bortezomib or High-Dose Dexamethasone for Relapsed Multiple Myeloma
Richardson, P. G., Sonneveld, P., Schuster, M. W., Irwin, D., Stadtmauer, E. A., Facon, T., Harousseau, J.-L., Ben-Yehuda, D., Lonial, S., Goldschmidt, H., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043445 · Cited by 2,491
Self-citationPalumbo, A., & Anderson, K. (2011) · New England Journal of Medicine · doi:10.1056/nejmra1011442 · Cited by 2,326
Self-citationImproved survival in multiple myeloma and the impact of novel therapies
Kumar, S. K., Rajkumar, S. V., Dispenzieri, A., Lacy, M. Q., Hayman, S. R., Buadi, F. K., Zeldenrust, S. R., Dingli, D., Russell, S. J., Lust, J. A., et al. (2008) · Blood · doi:10.1182/blood-2007-10-116129 · Cited by 2,240
Raje, N., & Anderson, K. C. (2000) · Current Treatment Options in Oncology · doi:10.1007/s11864-000-0017-x · Cited by 2,163
Self-citationLee, A.-H., Iwakoshi, N. N., & Glimcher, L. H. (2003) · Molecular and Cellular Biology · doi:10.1128/mcb.23.21.7448-7459.2003 · Cited by 2,037
McCullough, K. D., Martindale, J. L., Klotz, L.-O., Aw, T.-Y., & Holbrook, N. J. (2001) · Molecular and Cellular Biology · doi:10.1128/mcb.21.4.1249-1259.2001 · Cited by 1,889
Cell death and endoplasmic reticulum stress: disease relevance and therapeutic opportunities
Kim, I., Xu, W., & Reed, J. C. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2755 · Cited by 1,817
Cited by
The Role of Endoplasmic Reticulum Stress in Human Pathology
Oakes, S. A., & Papa, F. R. (2015) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-012513-104649 · Cited by 1,581
Endoplasmic Reticulum Stress and Oxidative Stress in Cell Fate Decision and Human Disease
Cao, S. S., & Kaufman, R. J. (2014) · Antioxidants & Redox Signaling · doi:10.1089/ars.2014.5851 · Cited by 1,363
“Several IRE1 endoribonuclease inhibitors, that prevent Xbp1 mRNA splicing and RIDD, exhibited therapeutic effect against multiple myeloma in vitro and/or in vivo (117,130,137).”
BackgroundEndoplasmic reticulum stress signals in the tumour and its microenvironment
Chen, X., & Cubillos-Ruiz, J. R. (2021) · Nature Reviews Cancer · doi:10.1038/s41568-020-00312-2 · Cited by 1,356
Endoplasmic reticulum stress signalling-from basic mechanisms to clinical applications
Almanza, A., Carlesso, A., Chintha, C., Creedican, S., Doultsinos, D., Leuzzi, B., Luís, A., McCarthy, N., Montibeller, L., More, S., et al. (2019) · The FEBS Journal · doi:10.1111/febs.14608 · Cited by 1,034
The impact of the unfolded protein response on human disease
Wang, S., & Kaufman, R. J. (2012) · Journal of Cell Biology · doi:10.1083/jcb.201110131 · Cited by 984
Metadata
- Authors
- Mimura, N., Fulciniti, M., Gorgun, G., Tai, Y.-T., Cirstea, D., Santo, L., Hu, Y., Fabre, C., Minami, J., Ohguchi, H., Kiziltepe, T., Ikeda, H., Kawano, Y., French, M., Blumenthal, M., Tam, V., Kertesz, N. L., Malyankar, U. M., Hokenson, M., Pham, T., Zeng, Q., Patterson, J. B., Richardson, P. G., Munshi, N. C., & Anderson, K. C.
- Affiliations
- Harvard University (US)
- Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA;
- MannKind Corporation (United States) (US)
- ORCID
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 2012-06-14
- Volume
- 119
- Issue
- 24
- Pages
- 5772-5781
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- PMC
- PMC3382937
- OpenAlex
- W1993401552
- Cited by
- 432
- References
- 46
- Citations by year
- 2026: 13 · 2025: 26 · 2024: 21 · 2023: 22 · 2022: 36 · 2021: 29 · 2020: 49 · 2019: 46 · 2018: 29 · 2017: 32 · 2016: 32 · 2015: 31 · 2014: 36 · 2013: 24 · 2012: 5
- FWCI
- 14.69
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Locations
- Blood (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (5p01ca078378-15)
- U.S. Public Health Service (SPOREP50100707)
- National Cancer Institute (P01-CA078378, P50CA100707, R01CA050947)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Endoplasmic Reticulum Stress and Disease
- Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
- Health Sciences › Medicine › Hematology › Chronic Lymphocytic Leukemia Research
- Keywords
- multiple myeloma, IRE1α, XBP1 splicing, endoplasmic reticulum stress, unfolded protein response, bortezomib, 17-AAG, CHOP, apoptosis, mesenchymal stem cells, interleukin-6, small molecule inhibitors
- MeSH terms
- Bortezomib, Regulatory Factor X Transcription Factors, X-Box Binding Protein 1, Animals, Antineoplastic Combined Chemotherapy Protocols, Bone Marrow Cells, Boronic Acids, DNA-Binding Proteins, Endoribonucleases, Enzyme Activation, Enzyme Inhibitors, Humans, Multiple Myeloma, Pyrazines, RNA Splicing, RNA, Messenger, Transcription Factors, Signal Transduction, Interleukin-6, Benzoquinones, Cell Death, Stromal Cells, Protein Serine-Threonine Kinases, eIF-2 Kinase, Cell Line, Tumor, Lactams, Macrocyclic, Cell Proliferation, Mice, Unfolded Protein Response, Endoplasmic Reticulum Stress
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Blockade of XBP1 splicing by inhibition of IRE1α is a promising therapeutic option in multiple myeloma. https://app.cochat.ai/papers/10.1182/blood-2011-07-366633
- The paper
- Mimura, N., Fulciniti, M., Gorgun, G., Tai, Y.-T., Cirstea, D., Santo, L., Hu, Y., Fabre, C., Minami, J., Ohguchi, H., Kiziltepe, T., Ikeda, H., Kawano, Y., French, M., Blumenthal, M., Tam, V., Kertesz, N. L., Malyankar, U. M., Hokenson, M., . . . Anderson, K. C. (2012). Blockade of XBP1 splicing by inhibition of IRE1α is a promising therapeutic option in multiple myeloma. Blood. https://doi.org/10.1182/blood-2011-07-366633
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.